Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

被引：0
|
作者：
Hiroshi Yokouchi
Koichi Yamazaki
Ichiro Kinoshita
Jun Konishi
Hajime Asahina
Noriaki Sukoh
Masao Harada
Kenji Akie
Shigeaki Ogura
Takashi Ishida
Mitsuru Munakata
Hirotoshi Dosaka-Akita
Hiroshi Isobe
Masaharu Nishimura
机构：
[1] Hokkaido University School of Medicine,First Department of Medicine
[2] Hokkaido University Graduate School of Medicine,Department of Medical Oncology
[3] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine
[4] Sapporo City General Hospital,Department of Respiratory Disease
[5] Fukushima Medical University,Department of Pulmonary Medicine
[6] KKR Sapporo Medical Center,Department of Medical Oncology
[7] Hokkaido Lung Cancer Clinical Research Group,undefined
来源：
BMC Cancer | / 7卷
关键词：
Overall Survival; Epidermal Growth Factor Receptor; Bone Metastasis; Gefitinib; Epidermal Growth Factor Receptor Gene;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
    Yokouchi, Hiroshi
    Yamazaki, Koichi
    Kinoshita, Ichiro
    Konishi, Jun
    Asahina, Hajime
    Sukoh, Noriaki
    Harada, Masao
    Akie, Kenji
    Ogura, Shigeaki
    Ishida, Takashi
    Munakata, Mitsuru
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nishimura, Masaharu
    BMC CANCER, 2007, 7 (1)
  • [2] Clinical features of gefitinib-responders with non-small cell lung cancer
    Shenglin, M.
    Yaping, X.
    Qinghua, D.
    Xinmin, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
    Asahina, Hajime
    Oizumi, Satoshi
    Inoue, Akira
    Kinoshita, Ichiro
    Ishida, Takashi
    Fujita, Yuka
    Sukoh, Noriaki
    Harada, Masao
    Maemondo, Makoto
    Saijo, Yasuo
    Dosaka-Akita, Hirotoshi
    Isobe, Hiroshi
    Nukiwa, Toshihiro
    Nishimura, Masaharu
    ONCOLOGY, 2010, 79 (5-6) : 423 - 429
  • [4] Gefitinib in non-small cell lung cancer
    Tamura, K
    Fukuoka, M
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 985 - 993
  • [5] Effect of gefitinib challenge to initial treatment with non-small cell lung cancer
    Chen, Xiaofeng
    Li, Wei
    Hu, Xiaoli
    Geng, Yiting
    Wang, Rong
    Yin, Yongmei
    Shu, Yongqian
    BIOMEDICINE & PHARMACOTHERAPY, 2011, 65 (08) : 542 - 546
  • [6] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [7] Gefitinib for advanced non-small cell lung cancer
    Sim, Esther H. A.
    Yang, Ian A.
    Wood-Baker, Richard
    Bowman, Rayleen V.
    Fong, Kwun M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2018, (01):
  • [8] Gefitinib in advanced non-small cell lung cancer
    Sharma, R
    Boyer, M
    Clarke, S
    Millward, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (02) : 77 - 82
  • [9] Gefitinib Plus Paclitaxel after Failure of Gefitinib in Non-small Cell Lung Cancer Initially Responding to Gefitinib
    Shukuya, Takehito
    Takahashi, Toshiaki
    Tamiya, Akihiro
    Ono, Akira
    Igawa, Satoshi
    Nakamura, Yukiko
    Tsuya, Asuka
    Murakami, Haruyasu
    Naito, Tateaki
    Kaira, Kyoichi
    Endo, Masahiro
    Yamamoto, Nobuyuki
    ANTICANCER RESEARCH, 2009, 29 (07) : 2747 - 2751
  • [10] CLINICAL CHARACTERISTICS OF ACQUIRED RESISTANCE TO GEFITINIB IN NON-SMALL CELL LUNG CANCER
    Lee, Kye Young
    Kim, Hee Joung
    Kim, Young-Chul
    Shin, Kyeong-Cheol
    Lee, Jae Chol
    Ryu, Jeong Seon
    Jang, Seung Hoon
    Kim, Sun Young
    Jang, Tae Won
    RESPIROLOGY, 2010, 15 : 37 - 37
12345